Total selective synthesis of enantiopure O1-acyl-3-aminoalkane-1,2-diols by ring opening of aminoepoxides with carboxylic acids.

J Org Chem

Departamento de Química Orgánica e Inorgánica, Facultad de Química, Universidad de Oviedo, Julián Clavería, 8, 33071 Oviedo, Spain.

Published: December 2005

[reaction: see text] Synthesis of (2R,3S)- or (2S,3S)-O1-acyl-3-aminoalkane-1,2-diols by ring opening of enantiopure (2R,1'S)- or (2S,1'S)-2-(1-aminoalkyl)epoxides 1 or 2, with carboxylic acids in the presence of BF3 x Et2O and chlorotrimethylsilane, is described. The conversion takes place with total selectivity and in good yield. In addition, (2R,3S)-O,O-diacyl-3-aminoalkane-1,2-diols 3 were also prepared from reaction of (2R,1'S)-2-(1-aminoalkyl)epoxides 1 with carboxylic acids under the same reaction conditions and without chlorotrimethylsilane. Mechanisms to explain both transformations are proposed.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jo0514873DOI Listing

Publication Analysis

Top Keywords

carboxylic acids
12
ring opening
8
total selective
4
selective synthesis
4
synthesis enantiopure
4
enantiopure o1-acyl-3-aminoalkane-12-diols
4
o1-acyl-3-aminoalkane-12-diols ring
4
opening aminoepoxides
4
aminoepoxides carboxylic
4
acids [reaction
4

Similar Publications

Recent advances in engineering non-native microorganisms for poly(3-hydroxybutyrate) production.

World J Microbiol Biotechnol

January 2025

Biofuels Institute, School of the Environment and Safety Engineering, Jiangsu University, Zhenjiang, 212013, China.

Poly(3-hydroxybutyrate) (PHB) is a biodegradable polymer that belongs to a group of polymers called polyhydroxyalkanoates (PHAs). PHB can be synthesized from renewable resources, making it a promising alternative to petroleum-derived plastics. It is also considered non-toxic, biodegradable, and biocompatible, which makes it suitable for various applications in the medicine and biomedicine.

View Article and Find Full Text PDF

Can you have a cake and eat it? Comparing reducing mycophenolate versus switching to everolimus for kidney transplants with new-onset BKPyV-DNAemia.

Kidney Int

February 2025

Transplantation & Clinical Virology, Department of Biomedicine, University of Basel, Basel Switzerland. Electronic address:

BK polyomavirus remains a vexing issue in kidney transplantation. There are no antiviral drugs, and solely reducing immunosuppression is recommended for management. However, evidence from randomized controlled studies lacks defining clearance of BK polyomavirus-DNAemia and/or nephropathy as a primary outcome.

View Article and Find Full Text PDF

Carboxylic acids and aromatic compounds are essential building blocks and starting materials for the production of a wide range of fine chemicals and materials. Their recovery from kraft black liquor, an industrial effluent from pulp and paper mills, is a promising way to produce alternative bio-based chemicals. Reliable methods are needed to identify and quantify the molecules of interest in complex mixtures such as black liquors.

View Article and Find Full Text PDF

Europe previously approved tecovirimat for mpox, based on animal data; the U.S. has stockpiled it for smallpox.

View Article and Find Full Text PDF

Background: Approval of proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies (mAbs), such as daratumumab, has reshaped treatment patterns in patients with multiple myeloma (MM) in Japan. This retrospective study evaluated patient characteristics, treatment patterns, and trends in MM patients using Medical Data Vision, the largest electronic health records database in Japan with anonymous inpatient and outpatient health information.

Methods: Patients aged ≥18 years, with ≥2 records of an MM diagnostic and disease code and ≥1 record of MM treatment between 01 April 2008 and 30 June 2023 were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!